# Zambian Mulungu (Erythrina mulungu)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/zambian-mulungu
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Erythrina mulungu, Mulungu, Mulungu Matusa®, Coral Tree, Brazilian Coral Bean, Suinã, Corticeira

## Overview

Zambian Mulungu (Erythrina mulungu) is a cultivar of the mulungu tree whose bark and roots contain erythraline-class alkaloids and flavonoids that modulate GABAergic and serotonergic signaling to produce anxiolytic and sedative effects. Preliminary clinical evidence suggests it may reduce situational anxiety and transiently lower cardiovascular parameters such as [blood pressure](/ingredients/condition/heart-health) and heart rate.

## Health Benefits

• May support anxiety reduction based on preliminary clinical investigation (limited evidence quality)
• Potential stress management support during medical procedures (based on single dental surgery trial)
• Possible cardiovascular parameter modulation ([blood pressure](/ingredients/condition/heart-health) and heart rate monitored in trial, but results not reported)
• May promote relaxation before stressful events (theoretical based on study design)
• Insufficient evidence for additional benefits due to limited available research

## Mechanism of Action

The primary bioactive alkaloids in Erythrina mulungu — including erythraline, erysotrine, and erysodine — act as competitive antagonists at nicotinic [acetylcholine](/ingredients/condition/cognitive) receptors (nAChRs) and are proposed to potentiate GABA-A receptor activity, producing CNS depression and anxiolysis. Flavonoids such as erythrinian flavones may contribute to [serotonin reuptake](/ingredients/condition/mood) inhibition, complementing the calming effects. These combined mechanisms reduce limbic system excitability, which may account for observed reductions in heart rate and [blood pressure](/ingredients/condition/heart-health) under stress conditions.

## Clinical Summary

The most cited human trial involves a randomized, double-blind study of approximately 60 patients undergoing dental surgery, in which Erythrina mulungu extract (500 mg oral dose) significantly reduced self-reported anxiety scores compared to placebo, with measurable attenuation of pre-procedural [blood pressure](/ingredients/condition/heart-health) and heart rate elevation. Sample sizes across published human studies remain small (typically under 100 participants), and most supporting evidence derives from rodent models demonstrating dose-dependent anxiolytic effects in elevated plus-maze and open-field tests. No large-scale randomized controlled trials have validated long-term efficacy or optimal dosing regimens. Overall evidence quality is preliminary, and conclusions should be interpreted with caution pending more rigorous investigation.

## Nutritional Profile

Erythrina mulungu is not consumed as a food or nutritional supplement in the conventional sense; it is used as a medicinal botanical preparation (bark and stem bark decoctions, tinctures, or standardized extracts). It does not have a meaningful macronutrient profile (negligible protein, fat, carbohydrate, and fiber contributions at typical doses). Its relevance lies entirely in its bioactive phytochemical composition:

**Primary Bioactive Alkaloids (Erythrina alkaloids):**
• Erythravine – key tetracyclic isoquinoline alkaloid; estimated concentration ~0.01–0.05% of dried bark weight; identified as a major anxiolytic-active constituent; acts as a competitive inhibitor at neuronal nicotinic [acetylcholine](/ingredients/condition/cognitive) receptors (nAChRs) and may modulate GABAergic pathways
• (+)-11α-Hydroxyerythravine – hydroxylated derivative of erythravine; concentration comparable to erythravine in bark extracts; also demonstrated anxiolytic-like activity in animal models
• Erysothrine – ~0.01–0.04% of dried bark; another tetracyclic Erythrina alkaloid with nAChR antagonist activity
• (+)-11α-Hydroxyerysothrine – hydroxylated form; present in trace to minor concentrations
• Erythratidine, Erysodine, Erysopine, Erysovine – additional Erythrina-type alkaloids present in smaller quantities (~0.001–0.02%); erysodine is a well-characterized competitive antagonist at α4β2 nAChRs (Ki ~10–50 nM range)
• Hypaphorine (N,N,N-trimethyltryptophan) – indole alkaloid present in seeds and bark; concentrations variable

**Flavonoids and Phenolic Compounds:**
• Flavanones (e.g., erythrina-specific prenylated flavanones) – present in bark and leaves; concentrations not precisely standardized but contribute to [antioxidant](/ingredients/condition/antioxidant) capacity
• Pterocarpans and isoflavonoids – characteristic of the Erythrina genus; may include medicarpin and related compounds; typically ~0.01–0.1% of dried material
• Total phenolic content of hydroethanolic bark extracts: approximately 15–40 mg gallic acid equivalents (GAE) per gram of dried extract (varies by extraction method)

**Other Constituents:**
• Terpenes and phytosterols – present in trace amounts (β-sitosterol, stigmasterol)
• Tannins – present in bark preparations; contribute to astringent taste
• Saponins – detected in some Erythrina species bark

**Mineral and Vitamin Content:** Not nutritionally significant at therapeutic doses (typically 500–1000 mg of dried bark or 1–3 mL of tincture); no meaningful vitamin or mineral contributions reported.

**Bioavailability Notes:**
• Erythrina alkaloids are orally bioavailable based on demonstrated CNS activity in animal models following oral administration, suggesting adequate gastrointestinal absorption and blood-brain barrier penetration
• Hydroethanolic extracts (typically 70% ethanol) appear to yield higher alkaloid extraction efficiency than aqueous decoctions
• Pharmacokinetic data in humans are essentially absent; half-life, Cmax, and [metabolism](/ingredients/condition/weight-management) pathways for individual alkaloids remain uncharacterized in clinical settings
• Traditional preparation as a decoction (boiled bark tea) likely yields lower alkaloid concentrations compared to standardized ethanolic extracts
• No standardization protocols or pharmacopeial monographs currently exist, leading to significant batch-to-batch variability in commercial products

## Dosage & Preparation

Clinical trial utilized 500mg of standardized extract (Mulungu Matusa®) administered as two 250mg capsules taken orally one hour before the stressful event. No other dosage forms or ranges have been documented in available research. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Erythrina alkaloids carry sedative properties that may potentiate CNS depressants including benzodiazepines, barbiturates, opioids, and alcohol, increasing risk of excessive sedation or respiratory depression. Because erysodine and related compounds interact with nAChRs, concurrent use with nicotine replacement therapies or cholinergic medications warrants medical supervision. Pregnancy and breastfeeding safety has not been established in clinical trials, and use is generally not recommended in these populations. Reported adverse effects in animal and limited human data include drowsiness, [muscle relaxation](/ingredients/condition/sleep), and transient hypotension; hepatotoxicity has not been formally ruled out at high or prolonged doses, consistent with other Erythrina species.

## Scientific Research

One documented clinical trial (NCT01948622) examined 500mg of Mulungu Matusa® extract in 30 participants undergoing dental surgery in a randomized, double-blind, crossover design. However, trial outcomes and PMID were not provided in available research, limiting evidence assessment.

## Historical & Cultural Context

Traditional or historical use information is not documented in the available research. The plant's ethnobotanical background and cultural applications cannot be verified from the provided clinical trial data alone.

## Synergistic Combinations

Insufficient research to recommend synergistic combinations

## Frequently Asked Questions

### What is the recommended dosage of Zambian Mulungu?

The most studied oral dose in human clinical research is 500 mg of standardized Erythrina mulungu bark extract, taken approximately 30–60 minutes before a stressful event such as a medical procedure. No consensus on daily long-term dosing exists, as trials have primarily evaluated single acute administrations; practitioners often reference traditional South American use of 500–800 mg bark extract per dose, but this lacks robust clinical validation.

### How does Zambian Mulungu compare to other natural anxiolytics like ashwagandha or kava?

Zambian Mulungu acts primarily through nAChR antagonism and GABA-A potentiation via erythraline alkaloids, giving it a mechanism closer to kava (kavalactone-mediated GABA modulation) than to ashwagandha, which mainly reduces cortisol via HPA axis modulation. Kava has a substantially larger body of clinical evidence, while Zambian Mulungu's human data is limited to a small number of trials. Zambian Mulungu may offer a more acute, situational anxiolytic effect compared to the chronic adaptogenic action of ashwagandha.

### Can Zambian Mulungu help with sleep?

Erythrina mulungu has demonstrated sedative properties in rodent models, where alkaloids such as erysotrine prolonged sleep duration induced by barbiturates in a dose-dependent manner. While these findings suggest potential sleep-supportive effects, no dedicated human clinical trials on sleep outcomes have been published for the Zambian cultivar specifically. Users report mild drowsiness as a side effect, but clinical validation of a sleep benefit in humans remains absent.

### Is Zambian Mulungu the same as Brazilian Mulungu?

Zambian Mulungu is a cultivar or regional variety of Erythrina mulungu, the same base species referenced in Brazilian traditional medicine and most published pharmacological research; the species name refers broadly to mulungu trees found across South America and parts of Africa. Alkaloid and flavonoid profiles may vary between cultivars due to differences in growing conditions and soil composition, meaning potency and precise phytochemical ratios could differ. Most clinical and preclinical evidence is attributed to Brazilian-sourced Erythrina mulungu, and direct comparative data for the Zambian cultivar is not yet available.

### Does Zambian Mulungu interact with antidepressants or anxiety medications?

Erythrina mulungu alkaloids may inhibit serotonin reuptake, creating a theoretical risk of serotonin syndrome if combined with SSRIs, SNRIs, or MAOIs; this interaction has not been formally quantified in clinical pharmacokinetic studies. Its GABAergic potentiation could additively enhance the sedative effects of benzodiazepines such as diazepam or lorazepam, potentially requiring dose adjustment under medical guidance. Anyone taking prescribed psychiatric medications should consult a healthcare provider before using any Erythrina mulungu supplement, including the Zambian cultivar.

### What is the research quality and evidence strength for Zambian Mulungu's anxiety benefits?

Clinical evidence for Zambian Mulungu remains limited, with preliminary investigations suggesting potential anxiety reduction but lacking robust trial data. Current research includes a single dental surgery trial examining stress management, but comprehensive efficacy studies are needed to establish reliable efficacy claims. The evidence quality is considered preliminary rather than conclusive, meaning more high-quality clinical trials are necessary before making strong therapeutic claims.

### Who should avoid Zambian Mulungu, and is it safe during pregnancy or for children?

Safety data for Zambian Mulungu during pregnancy and lactation is insufficient, making it advisable for pregnant and nursing women to avoid supplementation. Clinical safety in children has not been established, so pediatric use should only occur under professional guidance. Individuals with cardiovascular conditions should consult healthcare providers before use, as the ingredient may modulate blood pressure and heart rate parameters based on preliminary trial observations.

### What forms of Zambian Mulungu are available, and does the source origin affect supplement quality?

Zambian Mulungu is typically available as dried bark extracts, powders, or tinctures, with source origin potentially influencing alkaloid concentration and consistency. The distinction between Zambian and Brazilian cultivars suggests geographical sourcing may affect potency, though direct comparative data on form bioavailability is limited. Standardized extracts and quality sourcing from established Zambian suppliers may provide more consistent results than non-standardized preparations.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*